Geriatric medicine

BMJ

Volumn 322, Issue 7278, 2001, Pages 86-

  Straus, Sharon E ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL BLOOD LEVEL; CORONARY RISK; GERIATRIC DISORDER; HEART FAILURE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; AGED; CONGESTIVE HEART FAILURE; DEMENTIA; FALLING; GERIATRICS; OSTEOPOROSIS;

ACCIDENTAL FALLS; AGED; DEMENTIA; GERIATRICS; HEART FAILURE, CONGESTIVE; HUMANS; OSTEOPOROSIS;

EID: 0035852588     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.322.7278.86     Document Type: Article

References (36)

1. Bureau of the Census. Current population reports. 65-plus in America. Washington DC: US Government Printing Office, 1993.
2. Partnerships in long-term healthcare. Toronto: Ministry of Health, 1993.
3. The Heart Outcomes Prevention Evaluation Study Investigators. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-153.
4. Lewis SJ, Moye LA, Sacks FM. The effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in average range. Results of the Cholesterol in Recurrent Events Trial. Ann Intern Med 1998; 129: 681-689.
5. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomised trials. JAMA 1997; 278: 313-321.
6. Lemaitre RN, Furberg CD, Newman AB, Hulley SB, Gordon DJ, Gottdiener JS, et al. Time trends in the use of cholesterol-lowering agents in older adults: the cardiovascular health study. Arch Intern Med 1998; 158: 1761-1768.
7. Ramsay LE, Williams B, Johnston GD, Macgregor GA, Boston L, Potter JF, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319: 630-635.
8. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 243-246.
9. Psaty BM, Savage PJ, Tell GS, Polak JF, Hirch CH, Gardin JM, et al. Temporal patterns of antihypertensive medication use among elderly patients. The cardiovascular health study. JAMA 1993; 270: 1837-1841.
10. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-1907.
11. Gueyffier F, Bulpitt C, Boissel J-P, et al, for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353: 793-796.
12. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomised trials. Circulation 1998; 98: 1184-1191.
13. Review: Beta-blockers reduce mortality in morbidity in congestive heart failure. ACP J Club 1999; 130: 7. Abstract of: Avezum A, Tsuyuki RT, Pogue J, Yusuf S. Beta-blocker therapy for congestive heart failure: a systematic overview and critical appraisal of the published trial. Can J Cardiol 1998; 14: 1045-53.
14. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999; 353: 2001-2007.
15. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekhus J, et al. Effects of controlled release metoprolol on total mortality, hospitalisations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283: 1295-1302.
16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al, for the Randomised Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
17. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ 1997; 314: 1151-1159.
18. Indredavik B, Slordahl SA, Bakke F, Rokseth R, Haheim LL. Stroke unit treatment. Long-term effects. Stroke 1997; 28: 1861-1866.
19. Indredavik B, Slordahl SA, Bakke F, Rokseth R, Haheim LL. Stroke unit treatment. 10 year follow-up. Stroke 1999; 30: 1524-1527.
20. Mayeux R, Sonders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E in the genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998; 338: 506-511.
21. Lopez Arrieta J, Rodriguez Rartalejo F. Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. Age Ageing 1998; 27: 161-179.
22. Rogers SL, Doody RS, Mohs RC, Friedhoff LT and the donepezil study group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-1031.
23. Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI, for the metrifonate study group. The effects of metrifonate on the cognitive, behavioural, and functional performance of Alzheimer's disease patients. J Clin Psychiatry 1999; 60: 318-325.
24. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-640.
25. Dawson-Hughs B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-676.
26. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effective alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 1996; 348: 1535-1541.
27. Ensrud KE, Black DM, Polermo L, Bauer DC, Barrett-Connor E, Quandt SD, et al. Treatment with alendronate prevents fractures in women at highest risks. Results from the fracture intervention trial. Arch Intern Med 1997; 157: 2617-2624.
28. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelson T, Genant HK, et al, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a three-year randomised clinical trial. JAMA 1999; 282: 637-645.
29. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomised trial. JAMA 1999; 281: 2189-2197.
30. Cryer PC, Davidson L, Styles CP, Langley JD. Descriptive epidemiology of injury in the south east: identifying priorities for action. Public Health 1996; 110: 331-338.
31. Kannus P, Parkkari J, Koskinen S, Niewi S, Palvaneri M, Jarvinen M, et al. Fall-induced injuries and deaths among older adults. JAMA 1999; 281: 1895-1899.
32. Tinetti ME, Williams CS. Falls, injuries due to falls and the risk of admission to a nursing home. N Engl J Med 1997; 337: 1279-1284.
33. Rizzo JA, Friedkin R, Williams CS, Nabors J, Acampora D, Tinetti ME. Health care utilisation and costs in a Medicare population by fall status. Med Care 1998; 36: 1174-1188.
34. Gillespie LD, Gillespie WJ, Cumming R, Lamb SE, Rowe BH. Interventions to reduce the incidence of falling in the elderly. In: Cochrane Collaboration,ed. Cochrane Library. Issue 2. Oxford: Update Software, 2000.
35. NHS Centre for Reviews and Dissemination. Preventing falls and subsequent injury in older people. Effective Health Care 1996; 2(4): 1-16.
36. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. In: Cochrane Collaboration,ed. Cochrane Library. Issue 2. Oxford: Update Software, 2000.